The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer

Cancer Research

Volumn 63, Issue 19, 2003, Pages 6244-6251

  Ayala, Gustavo ^a   Wang, Dagong ^b   Wulf, Gerburg ^c   Frolov, Anna ^a   Li, Rile ^a   Sowadski, Janusz ^b   Wheeler, Thomas M ^a   Lu, Kun Ping ^c   Bao, Lere ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Pintex Pharmaceuticals   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDYLPROLYL ISOMERASE PIN1; PROLYL ISOMERASE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN TARGETING; RECURRENCE RISK; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PEPTIDYLPROLYL ISOMERASE; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0141885095     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Greenlee, R. T., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 2000. CA Cancer J. Clin., 50: 7-33, 2000.
2. Abate-Shen, C., and Shen, M. M. Molecular genetics of PCa. Genes Dev., 14: 2410-2434, 2000.
3. Ruijter, E., van de Kaa, C., Miller, G., Ruiter, D., Debruyne, F., and Schalken, J. Molecular genetics and epidemiology of prostate carcinoma. Endocr. Rev., 20: 22-45, 1999.
4. Roberts, W. W., Bergstralh, E. J., Blute, M. L., Slezak, J. M., Carducci, M., Han, M., Epstein, J. I., Eisenberger, M. A., Walsh, P. C., and Partin, A. W. Contemporary identification of patients at high risk of early PCa recurrence after radical retropubic prostatectomy. Urology, 57: 1033-1037, 2001.
5. Han, M., Partin, A. W., Piantadosi, S., Epstein, J. I., and Walsh, P. C. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized PCa. J. Urol., 166: 416-419, 2001.
6. Stamey, T. A., Johnstone, I. M., McNeal, J. E., Lu, A. Y., and Yemoto, C. M. Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J. Urol., 167: 103-111, 2002.
7. Partin, A. W., Kattan, M. W., Subong, E. N. P., Walsch, P. C., Wojno, K. J., and Oesterling, J. E. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized PCa. J. Am. Med. Assoc., 277: 1445-1451, 1997.
8. Schroder, F. H., van der Cruijssen-Koeter, I., de Koning, H. J., Vis, A. N., Hoedemaeker, R. F., and Kranse, R. PCa detection at low prostate specific antigen. J. Urol., 163: 806-812, 2000.
9. Vazquez, F., and Sellers, W. R. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim. Biophys. Acta, 1470: M21-M35, 2000.
10. Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., and Chinnaiyan, A. M. Delineation of prognostic biomarkers in prostate cancer. Nature (Lond.), 412: 822-826, 2001.
11. Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., Lander, E. S., Loda, M., Kantoff, P. W., Golub, T. R., and Sellers, W. R. Gene, expression correlates of clinical prostate cancer behavior. Cancer Cell, 1: 203-209, 2002.
12. Blume-Jensen, P., and Hunter, T. Oncogenic kinase signalling. Nature (Lond.), 411: 355-365, 2001.
13. Hanahan, D., and Weinberg, R. A. The hallmarks of cancer. Cell, 100: 57-70, 2000.
14. Lu, K. P., Liou, Y. C., and Zhou, X. Z. Pinning down the proline-directed phosphorylation signaling. Trends Cell Biol., 12: 164-172, 2002.
15. Lu, K. P., Hanes, S. D., and Hunter, T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature (Lond.), 380: 544-547, 1996.
16. Yaffe, M. B., Schutkowski, M., Shen, M., Zhou, X. Z., Stukenberg, P. T., Rahfeld, J., Xu, J., Kuang, J., Kirschner, M. W., Fischer, G., Cantley, L. C., and Lu, K. P. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science (Wash. DC), 278: 1957-1960, 1997.
17. Ranganathan, R., Lu, K. P., Hunter, T., and Noel, J. P. Structural and functional analysis of the mitotic peptidyl-prolyl isomerase Pin1 suggests that substrate recognition is phosphorylation dependent. Cell, 89: 875-886, 1997.
18. Shen, M., Stukenberg, P. T., Kirschner, M. W., and Lu, K. P. The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins. Genes Dev., 12: 706-720, 1998.
19. Lu, P. J., Wulf, G., Zhou, X. Z., Davies, P., and Lu, K. P. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature (Lond.), 399: 784-788, 1999.
20. Zhou, X. Z., Kops, O., Werner, A., Lu, P. J., Shen, M., Stoller, G., Küllertz, G., Stark, M., Fischer, G., and Lu, K. P. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol. Cell, 6: 873-883, 2000.
21. Winkler, K. E., Swenson, K. I., Kornbluth, S., and Means, A. R. Requirement of the prolyl isomerase Pin1 for the replication checkpoint. Science (Wash. DC), 287: 1644-1647, 2000.
22. Wulf, G. M., Ryo, A., Wulf, G. G., Lee, S. W., Niu, T., and Lu, K. P. Pin1 is overexpressed in breast cancer and potentiates the transcriptional activity of phosphorylated c-Jun towards the cyclin D1 gene. EMBO J., 20: 3459-3472, 2001.
23. Ryo, A., Nakamura, N., Wulf, G., Liou, Y. C., and Lu, K. P. Pin1 regulates turnover and subcellular localization of β-catenin by inhibiting its interaction with APC. Nat. Cell Biol., 3: 793-801, 2001.
24. Liou, Y. C., Ryo, R., Huang, H. K., Lu, P. J., Bronson, R., Fujimori, F., Uchidafl, U., Hunter, T., and Lu, K. P. Loss of Pin1 function in the mouse resembles the cyclin D1-null phenotypes. Proc. Natl. Acad. Sci. USA, 99: 1335-1340, 2002.
25. Stukenberg, P. T., and Kirschner, M. W. Pin1 acts catalytically to promote a conformational change in Cdc25. Mol. Cell, 7: 1071-1083, 2001.
26. Hsu, T., McRackan, D., Vincent, T. S., and Gert De Couet, H. Drosophila Pin1 prolyl isomerase Dodo is a MAP kinase signal responder during oogenesis. Nat. Cell Biol., 3: 538-543, 2001.
27. Kops, O., Zhou, X. Z., and Lu, K. P. Pin1 enhances the dephosphorylation of the C-terminal domain of the RNA polymerase II by Fcp1. FEBS Lett., 513: 305-311, 2002.
28. Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., and Weinberg, R. A. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell, 82: 621-630, 1995.
29. Fantl, V., Stamp, G., Andrews, A., Rosewell, I., and Dickson, C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev., 9: 2364-2372, 1995.
30. Gillett, C., Fantl, V., Smith, R., Fisher, C., Bartek, J., Dickson, C., Barnes, D., and Peters, G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res., 54: 1812-1817, 1994.
31. Bartkova, J., Lukas, J., Muller, H., Lutzhoft, D., Strauss, M., and Bartek, J. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer, 57: 353-361, 1994.
32. Ryo, A., Liou, Y. C., Wulf, G., Nakamura, N., Lee, S. W., and Lu, K. P. Pin1 is an E2F target gene essential for the Neu/Ras-induced transformation of mammary epithelial cells. Mol. Cell. Biol., 22: 5281-5295, 2002.
33. Wheeler, T., and Lebovitz, R. Fresh tissue harvest for research from prostatectomy specimens. Prostate, 25: 274-279, 1994.
34. Rubin, M. A., Dunn, R., Strawderman, M., and Pienta, K. J. Tissue microarray sampling strategy for PCa biomarker analysis. Am. J. Surg. Pathol., 26: 312-319, 2002.
35. Bao, L., Loda, M., Janmey, P. A., Stewart, R., Anand-Apte, B., and Zetter, B. R. Thymosin β15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer. Nat. Med., 2: 1322-1328, 1996.
36. Zincke, H., Oesterling, J. E., Blute, M. L., Bergstralh, E. J., Myers, R. P., and Barrett, D. M. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol., 152: 1850, 1994.
37. Benson, R. C., Jr., Tomera, K. M., Zincke, H., Fleming, T. R., and Utz, D. C. Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma confined to the prostate. J. Urol., 131: 1103, 1984.
38. Behrens, J., von Kries, J. P., Kuhl, M., Bruhn, L., Wedlich, D., Grosschedl, R., and Birchmeier, W. Functional interaction of β-catenin with the transcription factor LEF-1. Nature (Lond.), 382: 638-642, 1996.
39. Molenaar, M., van de Wetering, M., Oosterwegel, M., Peterson-Maduro, J., Godsave, S., Korinek, V., Roose, J., Destree, O., and Clevers, H. XTcf-3 transcription factor mediates β-catenin-induced axis formation in Xenopus embryos. Cell, 86: 391-399, 1996.
40. He, T. C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., and Kinzler, K. W. Identification of c-MYC as a target of the APC pathway. Science (Wash. DC), 281: 1509-1512, 1998.
41. Tetsu, O., and McCormick, F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature (Lond.), 398: 422-426, 1999.
42. Lu, P. J., Zhou, X. Z., Shen, M., and Lu, K. P. A function of WW domains as phosphoserine- or phosphothreonine-binding modules. Science (Wash. DC), 283: 1325-1328, 1999.
43. Verdecia, M. A., Bowman, M. E., Lu, K. P., Hunter, T., and Noel, J. P. Structural basis for phosphoserine-proline recognition by group IV WW domains. Nat. Struct. Biol., 7: 639-643, 2000.
44. Lu, P. J., Zhou, X. Z., Liou, Y. C., Noel, J. P., and Lu, K. P. Critical role of WW domain phosphorylation in regulating its phosphoserine-binding activity and the Pin1 function. J. Biol. Chem., 277: 2381-2384, 2002.
45. O arrest. Biochem. Biophys. Res. Commun., 265: 658-663, 1999.